Replimune Group, Inc. – NASDAQ:REPL
Founder-led company
Replimune Group stock price today
$5.26
-7
-57.1%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Replimune Group stock price monthly change
+18.34%
month
Replimune Group stock price quarterly change
+18.34%
quarter
Replimune Group stock price yearly change
+49.70%
year
Replimune Group key metrics
Market Cap | 944.39M |
Enterprise value | 781.76M |
P/E | -5.9 |
EV/Sales | N/A |
EV/EBITDA | -5.12 |
Price/Sales | N/A |
Price/Book | 1.55 |
PEG ratio | 0.20 |
EPS | N/A |
Revenue | N/A |
EBITDA | -170.03M |
Income | -165.68M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeReplimune Group stock price history
Replimune Group stock forecast
Replimune Group financial statements
Average Price Target
$19
Potential upside: 261.21%
Analysts Price target
Financials & Ratios estimates
| Dec 2021 | 0 | -29.67M | |
|---|---|---|---|
| Mar 2022 | 0 | -31.69M | |
| Mar 2023 | 0 | -49.23M | |
| Mar 2024 | 0 | -55.07M |
| Sep 2022 | 436095000 | 52.02M | 11.93% |
|---|---|---|---|
| Dec 2022 | 678550000 | 83.20M | 12.26% |
| Mar 2023 | 646591000 | 91.29M | 14.12% |
| Mar 2024 | 487722000 | 113.21M | 23.21% |
| Dec 2021 | -18.34M | -13.42M | 3.96M |
|---|---|---|---|
| Mar 2022 | -22.55M | -4.32M | 359K |
| Mar 2023 | -32.79M | -22.75M | -77K |
| Mar 2024 | -46.16M | 23.20M | -130K |
Replimune Group alternative data
| Sep 2023 | 284 |
|---|---|
| Oct 2023 | 284 |
| Nov 2023 | 284 |
| Dec 2023 | 284 |
| Jan 2024 | 284 |
| Feb 2024 | 284 |
| Mar 2024 | 284 |
| Apr 2024 | 284 |
| May 2024 | 284 |
| Jun 2024 | 331 |
| Jul 2024 | 331 |
Replimune Group other data
27.53%
-60.45%
of REPL is owned by hedge funds
81
-52
15.92M
-32.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 98084 |
| Jun 2024 | 0 | 15881 |
| Aug 2024 | 0 | 8938 |
| Nov 2024 | 0 | 12453 |
| Dec 2024 | 0 | 10000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | PATEL SUSHIL director, officer: Chief Execut.. | Common Stock | 10,000 | $12.42 | $124,200 | ||
Sale | XYNOS KONSTANTINOS officer: Chief Medical Officer | Common Stock | 7,246 | $10.78 | $78,112 | ||
Sale | SARCHI CHRISTOPHER officer: Chief Commercial Officer | Common Stock | 5,207 | $10.78 | $56,131 | ||
Sale | HILL EMILY LUISA officer: Chief Fi.. | Common Stock | 8,938 | $10.18 | $90,989 | ||
Sale | XYNOS KONSTANTINOS officer: Chief Medical Officer | Common Stock | 15,881 | $7.5 | $119,108 | ||
Sale | SARCHI CHRISTOPHER officer: Chief Commercial Officer | Common Stock | 2,218 | $6.47 | $14,350 | ||
Sale | SCHWENDENMAN ANDREW officer: Chief Accounting Officer | Common Stock | 2,298 | $6.47 | $14,868 | ||
Sale | LOVE COLIN officer: Chief Operating Officer | Common Stock | 17,615 | $6.47 | $113,969 | ||
Sale | ASTLEY-SPARKE PHILIP director, officer: Executive Ch.. | Common Stock | 37,928 | $6.47 | $245,394 | ||
Sale | COFFIN ROBERT director | Common Stock | 11,464 | $6.47 | $74,172 |
| Insider | Compensation |
|---|---|
| Dr. Robert Coffin Ph.D. (1965) Founder, Pres, Chief R&D Officer and Director | $759,520 |
Mr. Philip Astley-Sparke FSA (1971) Chief Executive Officer & Director | $759,520 |
Ms. Tanya N. Lewis M.S. (1971) Chief Devel. Operations Officer | $16,230 |
Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug
Delcath Systems: Growing Fast, But Business Model Is Fragile
Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma
Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch
Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment
General Electric's CFO Carolina Dybeck Happe Steps Down: C-Suite Transitions
Replimune: A Sell Ahead Of Cutaneous Squamous Cell Carcinoma Data
Revisiting Replimune
Replimune: Recent Developments Strengthen Bull Thesis
-
What's the price of Replimune Group stock today?
One share of Replimune Group stock can currently be purchased for approximately $5.26.
-
When is Replimune Group's next earnings date?
Unfortunately, Replimune Group's (REPL) next earnings date is currently unknown.
-
Does Replimune Group pay dividends?
No, Replimune Group does not pay dividends.
-
How much money does Replimune Group make?
Replimune Group has a market capitalization of 944.39M.
-
What is Replimune Group's stock symbol?
Replimune Group, Inc. is traded on the NASDAQ under the ticker symbol "REPL".
-
What is Replimune Group's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Replimune Group?
Shares of Replimune Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Replimune Group's key executives?
Replimune Group's management team includes the following people:
- Dr. Robert Coffin Ph.D. Founder, Pres, Chief R&D Officer and Director(age: 60, pay: $759,520)
- Mr. Philip Astley-Sparke FSA Chief Executive Officer & Director(age: 54, pay: $759,520)
- Ms. Tanya N. Lewis M.S. Chief Devel. Operations Officer(age: 54, pay: $16,230)
-
Is Replimune Group founder-led company?
Yes, Replimune Group is a company led by its founder Dr. Robert Coffin Ph.D..
-
How many employees does Replimune Group have?
As Jul 2024, Replimune Group employs 331 workers, which is 17% more then previous quarter.
-
When Replimune Group went public?
Replimune Group, Inc. is publicly traded company for more then 7 years since IPO on 20 Jul 2018.
-
What is Replimune Group's official website?
The official website for Replimune Group is replimune.com.
-
Where are Replimune Group's headquarters?
Replimune Group is headquartered at 500 Unicorn Park Drive, Woburn, MA.
-
How can i contact Replimune Group?
Replimune Group's mailing address is 500 Unicorn Park Drive, Woburn, MA and company can be reached via phone at +7 812229600.
-
What is Replimune Group stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Replimune Group in the last 12 months, the avarage price target is $19. The average price target represents a 261.21% change from the last price of $5.26.
Replimune Group company profile:
Replimune Group, Inc.
replimune.comExchange:
NASDAQ
Full time employees:
331
Industry:
Biotechnology
Sector:
Healthcare
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
500 Unicorn Park Drive
Woburn, MA 01801
Woburn, MA 01801
CIK: 0001737953
ISIN: US76029N1063
CUSIP: 76029N106
